Medicis Pharmaceutical Stock Price, News & Analysis (NYSE:MRX)

Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

About Medicis Pharmaceutical (NYSE:MRX)

Medicis Pharmaceutical logoMedicis Pharmaceutical Corporation (Medicis) together with its wholly owned subsidiaries is an independent specialty pharmaceutical company engaged in the development and marketing of products for the treatment of dermatological and aesthetic conditions in the United States and Canada. Medicis offers a range of products addressing various conditions or aesthetic improvements, including facial wrinkles. Its brands are DYSPORT (abobotulinumtoxinA) 300 Units for Injection, PERLANE Injectable Gel, RESTYLANE Injectable Gel, SOLODYN (minocycline HCl, USP) Extended Release Tablets, VANOS (fluocinonide) Cream 0.1%, ZIANA (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel and ZYCLARA (imiquimod) Cream 3.75% and 2.5%. As of December 31, 2011, it offered 27 branded products. On December 2, 2011, it acquired Graceway Pharmaceuticals, LLC (Graceway). On November 1, 2011, Medicis sold Medicis Technologies Corporation, formerly LipoSonix, Inc., to Solta Medical, Inc. (Solta).

Receive MRX News and Ratings via Email

Sign-up to receive the latest news and ratings for MRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Generic Pharmaceuticals


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding SharesN/A

Medicis Pharmaceutical (NYSE:MRX) Frequently Asked Questions

What is Medicis Pharmaceutical's stock symbol?

Medicis Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRX."

Who are some of Medicis Pharmaceutical's key competitors?

Who are Medicis Pharmaceutical's key executives?

Medicis Pharmaceutical's management team includes the folowing people:

  • Robert Roswell Chai-Onn, Executive Vice President, General Counsel, Secretary, Director (Age 44)
  • Howard Bradley Schiller, Officer, Director (Age 53)
  • Ryan Weldon, Officer, Director

How do I buy Medicis Pharmaceutical stock?

Shares of Medicis Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Medicis Pharmaceutical?

Medicis Pharmaceutical's mailing address is 8125 N Hayden Rd, SCOTTSDALE, AZ 85258-2463, United States. The healthcare company can be reached via phone at +1-212-5992000.

MarketBeat Community Rating for Medicis Pharmaceutical (MRX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  105 (Vote Outperform)
Underperform Votes:  122 (Vote Underperform)
Total Votes:  227
MarketBeat's community ratings are surveys of what our community members think about Medicis Pharmaceutical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Medicis Pharmaceutical (NYSE:MRX) Analyst Ratings History

No equities research coverage for this company has been tracked by MarketBeat


Medicis Pharmaceutical (NYSE:MRX) Earnings History and Estimates Chart

Earnings by Quarter for Medicis Pharmaceutical (NYSE:MRX)

Medicis Pharmaceutical (NYSE MRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2012Q3 2012$0.49$0.48ViewN/AView Earnings Details
8/8/2012$0.46$0.52ViewN/AView Earnings Details
5/8/2012$0.42$0.60ViewN/AView Earnings Details
2/27/2012Q4 2011$0.54$0.56ViewN/AView Earnings Details
11/8/2011$0.61$0.56ViewN/AView Earnings Details
8/8/2011$0.64$0.64ViewN/AView Earnings Details
5/5/2011$0.49$0.50ViewN/AView Earnings Details
2/25/2011$0.60$0.60ViewN/AView Earnings Details
11/4/2010Q3 2010$0.57$0.58ViewN/AView Earnings Details
8/5/2010Q2 2010$0.49$0.56ViewN/AView Earnings Details
5/5/2010Q1 2010$0.43$0.54ViewN/AView Earnings Details
2/25/2010Q4 2009$0.60$0.68ViewN/AView Earnings Details
11/4/2009Q3 2009$0.42$0.33ViewN/AView Earnings Details
8/5/2009Q2 2009$0.14$0.39ViewN/AView Earnings Details
5/7/2009Q1 2009$0.19$0.09ViewN/AView Earnings Details
2/25/2009Q4 2008$0.31$0.42ViewN/AView Earnings Details
11/10/2008Q3 2008$0.23$0.27ViewN/AView Earnings Details
8/5/2008Q2 2008$0.35$0.40ViewN/AView Earnings Details
5/8/2008Q1 2008$0.34$0.38ViewN/AView Earnings Details
2/27/2008Q4 2007$0.43$0.54ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Medicis Pharmaceutical (NYSE:MRX) Earnings Estimates

No earnings estimates for this company have been tracked by


Dividend History for Medicis Pharmaceutical (NYSE:MRX)

No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Medicis Pharmaceutical (NYSE MRX)

No insider trades for this company have been tracked by


Medicis Pharmaceutical (NYSE MRX) News Headlines

Medicis Pharmaceutical Corp (MRX) versus Depomed (DEPO) Critical SurveyMedicis Pharmaceutical Corp (MRX) versus Depomed (DEPO) Critical Survey - November 23 at 9:14 PM
Head to Head Comparison: Depomed (DEPO) and Medicis Pharmaceutical Corp (MRX)Head to Head Comparison: Depomed (DEPO) and Medicis Pharmaceutical Corp (MRX) - November 8 at 5:31 PM

SEC Filings

Medicis Pharmaceutical (NYSE:MRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Medicis Pharmaceutical (NYSE:MRX) Income Statement, Balance Sheet and Cash Flow Statement


Medicis Pharmaceutical (NYSE MRX) Stock Chart for Sunday, February, 25, 2018

Loading chart…

This page was last updated on 2/25/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.